Allogene Therapeutics, Inc. 8-K

What Happened
Allogene Therapeutics, Inc. (ALLO) reported on Form 8‑K that on April 14, 2026 it entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC to sell 87,500,000 shares of its common stock at $2.00 per share. Gross proceeds are expected to be approximately $175.0 million before underwriting discounts, commissions and offering expenses. The offering is expected to close on April 16, 2026, subject to customary closing conditions. The company also granted the underwriters a 30‑day option to purchase up to an additional 13,125,000 shares at the public offering price less underwriting discounts and commissions. The offering is made under Allogene’s effective Form S‑3 registration statement.

Key Details

• Offering size: 87,500,000 shares at $2.00 per share; gross proceeds ≈ $175.0 million (before fees).
• Overallotment option: 30‑day option to buy up to 13,125,000 additional shares (brings total to 100,625,000 if exercised).
• Use of proceeds: net proceeds expected to be used for general corporate purposes, potentially including clinical trial expenses, R&D, general & administrative expenses, and capital expenditures.
• Timing and parties: Underwriting agreement dated April 14, 2026; expected close April 16, 2026; lead underwriters are Goldman Sachs, Jefferies and TD Securities. Press releases announcing the offering and pricing were issued April 13 and April 14, 2026.

Why It Matters
This offering will raise new capital for Allogene’s operations and development programs, which the company says may fund clinical trials and R&D. For existing shareholders, the issuance of 87.5 million new shares (and up to 13.125 million more if the option is exercised) represents dilution of current equity. The financing and its timing are material events that can affect liquidity, runway and the company’s financing strategy; completion is subject to customary closing conditions.